Science Current Events | Science News | Brightsurf.com
 

New analysis helps guide use of erlotinib in advanced non-small cell lung cancer

April 18, 2012
Patients with advanced non-small cell lung cancer should only receive treatment with the drug erlotinib before receiving standard chemotherapy if their tumor is known to harbor EGFR mutations, researchers report at the 3rd European Lung Cancer Conference in Geneva, Switzerland.

The results of biomarker analyses of a recently reported clinical trial confirm that patients with unknown or negative mutation status should be treated with the standard chemotherapy first, they say.

The TORCH trial was a randomized phase III trial conducted in Italy and Canada, which compared the efficacy of treatment with erlotinib, followed at progression of disease by cisplatin and gemcitabine, against the standard reverse sequence. Erlotinib is a drug that specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase.

The primary endpoint of the original TORCH study was overall survival and 900 patients were planned, however the study was stopped early as the first interim analysis showed that the erlotinib-first regimen was inferior to the standard approach.

In the new study, Dr Ming Tsao and colleagues conducted an exploratory analysis on the TORCH patient tumor samples that were available for analysis, looking for molecular biomarkers known to be potential predictors of benefit from EGFR inhibitors.

"Our results show a significant interaction in progression-free survival favoring treatment with erlotinib first in EGFR-mutated patients, and favouring first treatment with chemotherapy in EGFR wild type [non-mutated] patients," said Dr Tsao, from the Princess Margaret Hospital.

"However there was no significant interaction between treatment efficacy and overall survival. This shows that using erlotinib to treat patients with a mutated tumor is always effective, both in first and in second line; of course, it is much more convenient for these patients to receive it as first line, as shown also in other trials," Dr Tsao said.

Patients with EGFR mutations benefit from the erlotinib-first regimen because their tumors are very sensitive to the anti-tumor activity of the drug, he explained.

"The take-home message from this study is that in advanced non-small cell lung cancer patients, treatment with erlotinib first should only be applied to patients whose tumor is known to harbor EGFR mutation," said Dr Tsao. "Patients with unknown or negative mutation status should be treated with the standard chemotherapy first."

Commenting on the study which he was not involved in, Dr Tetsuya Mitsudomi from Aichi Cancer Center Hospital in Nagoya, Japan, member of the IASLC Board of Directors, said: "Many previous trials, for instance IPASS, NEJ002, WJTOG3405, OPTIMAL, EUROTAC, have already shown that EGFR mutation is the most reliable predictive marker for EGFR-TKI treatment. The current paper was able to confirm the importance of EGFR mutation testing when considering the use of erlotinib, especially in consideration of the far shorter progression-free survival obtained with erlotinib when the mutation was absent. Consequently, although it was thought that erlotinib is active even in lung cancer patients without EGFR mutation if compared with gefitinib, this study suggests that erlotinib should be avoided when treating patients without EGFR mutation, at least in the first-line setting."

This biomarker analysis was preplanned but actually only 36% of the samples could be anlayzed for EGFR mutation. This relatively low tissue accrual rate is precedented by many clinical trials in which the mutation analysis was performed retrospectively. "Therefore, we also have to consider prospective determination of oncogene mutation when we want to raise this rate such as in NEJ, WJTOG, OPTIMAL and EUROTAC," Dr Mitsudomi added.

"In summary, the TORCH-BIO study adds imprortant evidence to the research field of EGFR-TKI in lung cancer and emphazizes the importance of biomarker study for improvement of clinical outcome."

European Society for Medical Oncology


Related Erlotinib Current Events and Erlotinib News Articles


Blood samples as surrogates for tumor biopsies in patients with lung cancer
A study examined the feasibility of using circulating free DNA (cfDNA) from blood samples of patients with advanced non-small-cell lung cancer as a surrogate for tumor biopsies to determine tumor-causing epidermal growth factor receptor (EGFR) mutations and then correlate that with expected patient outcomes, according to a study published online by JAMA Oncology.

Stereotactic body radiation therapy plus chemotherapy improves survival among stage 4 lung cancer patients
A clinical trial that combined stereotactic body radiation therapy with a specific chemotherapy regimen more than doubled survival rates for certain stage 4 lung cancer patients, UT Southwestern Medical Center cancer researchers report.

Widely used osteoporosis drugs may prevent breast, lung and colon cancers
The most commonly used medications for osteoporosis worldwide, bisphosphonates, may also prevent certain kinds of lung, breast and colon cancers, according to two studies led by researchers at the Icahn School of Medicine at Mount Sinai and published today in the Proceedings of the National Academy of Sciences (PNAS).

Kidney cancer patients respond well to a combination of 2 existing anti-cancer drugs
Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anti-cancer drugs.

Study May Explain Why Targeted Drug Doesn't Benefit Patients With Early-Stage Lung Cancer
The drug erlotinib is highly effective in treating advanced-stage lung cancer patients whose tumors have a particular gene change, but when the same drug is used for patients with early-stage tumors with the same gene change, they actually fare worse than if they took nothing.

Drug-Target Database Lets Researchers Match Old Drugs to New Uses
There are thousands of drugs that silence many thousands of cancer-causing genetic abnormalities.

Chemotherapy timing is key to success
MIT researchers have devised a novel cancer treatment that destroys tumor cells by first disarming their defenses, then hitting them with a lethal dose of DNA damage.

Cancer stem cells linked to drug resistance
Most drugs used to treat lung, breast and pancreatic cancers also promote drug-resistance and ultimately spur tumor growth.

Immunotherapy data heralds new era of lung cancer treatment
A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumour cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress.

Targeted drug may prolong survival of patients with cervical cancer
A new clinical study has found that erlotinib, a targeted antitumor agent, has promising potential to improve treatment for cervical cancer.
More Erlotinib Current Events and Erlotinib News Articles

Erlotinib: Webster's Timeline History, 2003 - 2007

Erlotinib: Webster's Timeline History, 2003 - 2007
by Icon Group International (Author)


Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Erlotinib," including when used in literature (e.g. all authors that might have Erlotinib in their name). As such, this book represents the largest compilation of timeline events associated with Erlotinib when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social sciences...

  Erlotinib, gefitinib nip lung cancer mortality.(Pulmonary Medicine): An article from: Internal Medicine News
by Erik L. Goldman (Author)


This digital document is an article from Internal Medicine News, published by International Medical News Group on September 1, 2004. The length of the article is 609 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Erlotinib, gefitinib nip lung cancer mortality.(Pulmonary Medicine)
Author: Erik L. Goldman
Publication: Internal Medicine News (Magazine/Journal)
Date: September 1, 2004
Publisher: International Medical News Group
Volume: 37 Issue: 17 Page: 24(1)

Distributed by Thomson...

  Erlotinib: An entry from Thomson Gale's Gale Encyclopedia of Cancer, 2nd ed.
by Tish, A. M. Davidson (Author)


Students, researchers, and patients can find reliable, up-to-date and clearly written information in “The Gale Encyclopedia of Cancer,” a comprehensive survey of 120 cancers, cancer drugs, traditional and alternative treatments and diagnostic procedures.

  Bevacizumab-erlotinib combo boosts lung cancer survival.(Pulmonary Medicine)(cancer medicine): An article from: Family Practice News
by Jane Salodof MacNeil (Author)


This digital document is an article from Family Practice News, published by Thomson Gale on September 1, 2006. The length of the article is 713 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab-erlotinib combo boosts lung cancer survival.(Pulmonary Medicine)(cancer medicine)
Author: Jane Salodof MacNeil
Publication: Family Practice News (Magazine/Journal)
Date: September 1, 2006
Publisher: Thomson Gale
Volume: 36 Issue: 17 Page: 43(1)

Distributed by Thomson...

Lung Cancer

Lung Cancer
by Jack A. Roth (Editor), James D. Cox (Editor), Waun Ki Hong (Editor)


Lung cancer is a major cause of cancer-related deaths in men and women. However, since the first edition of Lung Cancer was published 14 years ago, rapid progress in the biology, prevention, diagnosis, and treatment of the disease has been made.

Breast Cancer in the Post-Genomic Era (Current Clinical Oncology)

Breast Cancer in the Post-Genomic Era (Current Clinical Oncology)
by Antonio Giordano (Editor), Nicola Normanno (Editor)


Breast Cancer is the most common tumor in women and the second leading cause of cancer deaths worldwide. Due to breakthroughs in gene profiling, the knowledge of the pathophysiology of the mammary gland had greatly increased over the last decade. In Breast Cancer in the Post Genomic Era, Antonio Giordano, Nicola Normanno, and a panel of international authorities in their field provide a comprehensive approach to the biology, diagnosis, prevention, and treatment of human breast carcinoma. The book provides a comprehensive approach to breast cancer, describing the use of gene profiling techniques to distinguish specific features of individual carcinomas, as well as emerging novel therapeutic approaches to treatment. Additional chapters cover the use of transgenic mice to model human breast...

Targeted Therapies: Mechanisms of Resistance (Molecular and Translational Medicine)

Targeted Therapies: Mechanisms of Resistance (Molecular and Translational Medicine)
by Daniel Gioeli (Editor)


This volume explores the mechanisms of resistance to targeted therapeutics. The focus is on the cancer cell signaling network, although other mechanisms of resistance including target mutation, and new areas of study such as cancer stem cells are included.Targeted Therapies: Mechanisms of Resistance highlights examples of changes in the signaling network in response to inhibition of a signaling event and underscores the importance in having a mechanistic understanding of the signaling network in cancer for developing effective targeted cancer therapies. Moreover, cutting edge tools to analyze the cell signaling network will be discussed. This includes the leading edge of techniques as well as computational biology and systems theory. This volume provides the reader with both an overview...

Methods of Cancer Diagnosis, Therapy and Prognosis: General Methods and Overviews, Lung Carcinoma and Prostate Carcinoma

Methods of Cancer Diagnosis, Therapy and Prognosis: General Methods and Overviews, Lung Carcinoma and Prostate Carcinoma
by M. A. Hayat (Editor)


Cancer is the leading cause of death, in the number of older cancer patients is after cardiovascular diseases, in the expected. Approximately, 77% of all types United States. A total of ? 1,399,790 new of cancers are diagnosed in persons of 55 cancer cases and ? 564,830 deaths were years and older. It was estimated that o- reported in the year 2006 in the country. third of the 559,650 cancer deaths in 2007 Approximately, one in every two men and in the United States were related to ov- one in every three women in the country weight or obesity, physical inactivity, and will have some type of cancer during nutrition, and thus could also be prevented their lifetime. Healthcare costs exceed (Am. Cancer Society, 2007). However, 1. 7 trillion dollars per year in the United in developed...

Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Second Edition

Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Second Edition
by Ronald Bukowski (Editor), Robert A. Figlin (Editor), Robert Motzer (Editor)


In the second edition of their critically acclaimed book, Ronald Bukowski, Robert Motzer, and Robert Figlin have thoroughly updated and expanded their survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. A panel of internationally renowned contributors explores the latest developments in molecular genetics, focusing on the novel targets that have been discovered in epithelial renal tumors. The discussion includes the specific biology of selected target molecules or receptors and the various agents that inhibit these targets, including full chapters devoted to drugs that selectively inhibit receptor tyrosine kinases, such as sunitinib and axitinib. Further attention is paid to leading-edge strategies that target and inhibit tumor...

Advances in Radiation Oncology in Lung Cancer (Medical Radiology / Radiation Oncology)

Advances in Radiation Oncology in Lung Cancer (Medical Radiology / Radiation Oncology)
by Branislav Jeremic (Editor)


This is the second, completely updated edition of a comprehensive book in which many of the world’s leading lung cancer specialists discuss the recent advances in the radiation oncology of lung cancer and reflect on the latest research findings. The first three sections cover the basic science of lung cancer, clinical investigations, including histology and staging, and a wide range of fundamental treatment considerations. Current treatment strategies for small cell and non-small cell lung cancer are then explained and evaluated in detail, with due attention to novel approaches that promise further improvements in outcome. The various types of treatment-related toxicity are discussed, and quality of life studies and prognostic factors are also considered. After evaluating the latest...

© 2015 BrightSurf.com